loading page

Obesity in Children with Acute Promyelocytic Leukemia: What is its Incidence and Prognostic Significance?
  • +9
  • Kathryn Laurie,
  • Paul Lee,
  • Alfred Rademaker,
  • Todd Alonzo,
  • Yi-Cheng Wang,
  • Bayard Powell,
  • Diana Wu,
  • Richard Larson,
  • John Gregory,
  • Matthew Kutny,
  • Nobuko Hijiya,
  • James Feusner
Kathryn Laurie
Goryeb Children's Hospital
Author Profile
Paul Lee
AbbVie Inc
Author Profile
Alfred Rademaker
Northwestern University Feinberg School of Medicine
Author Profile
Todd Alonzo
University of Southern California
Author Profile
Yi-Cheng Wang
Children\'s Oncology Group
Author Profile
Bayard Powell
Wake Forest Baptist Comprehensive Cancer Center
Author Profile
Diana Wu
St Jude Children's Research Hospital
Author Profile
Richard Larson
University of Chicago
Author Profile
John Gregory
Morristown Memorial Hospital
Author Profile
Matthew Kutny
University of Alabama at Birmingham
Author Profile
Nobuko Hijiya
Columbia University
Author Profile
James Feusner
UCSF Benioff Children's Hospital Oakland
Author Profile

Abstract

Objective: To compare outcomes data of obese and non-obese pediatric patients with acute promyelocytic leukemia from the Cancer and Leukemia Group B trial C9710 and the Children’s Oncology Group trial AAML0631. Methods: Data including demographics, adverse events, overall survival and event free survival was analyzed, with a focus on mortality in obese patients. Results: The incidence of obesity was 34% on C9710 and 35% on AAML0631. There was significantly lower overall survival in the obese population on AAML0631. Thirteen patients died during therapy or in follow up; seven of these occurred during induction. Conclusion: The incidence of obesity is higher in patients with APL compared to the general population. The presence and degree of obesity can influence OS on the most current treatment regimen. This implies the need for close management of obese patients at diagnosis as well as reinforces the need for further research on obesity driven APL

Peer review status:IN REVISION

20 Jul 2021Submitted to Pediatric Blood & Cancer
20 Jul 2021Assigned to Editor
20 Jul 2021Submission Checks Completed
28 Jul 2021Reviewer(s) Assigned
20 Aug 2021Review(s) Completed, Editorial Evaluation Pending
21 Aug 2021Editorial Decision: Revise Major